Quarterly report pursuant to Section 13 or 15(d)

License and Transfer Agreement - Additional Information (Detail)

v3.5.0.2
License and Transfer Agreement - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Apr. 18, 2016
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Contingencies And Commitments [Line Items]          
Research and development expense   $ 4,621,957 $ 2,051,688 $ 12,781,489 $ 5,301,911
License And Transfer Agreement [Member]          
Contingencies And Commitments [Line Items]          
Agreement termination notice period 30 days        
License And Transfer Agreement [Member] | Enumeral Biomedical Holdings Inc [Member]          
Contingencies And Commitments [Line Items]          
Upfront license fee payment $ 250,000        
Maintenance fee payment $ 750,000        
Agreement termination notice period upon material breach by the Company 60 days        
Agreement termination notice period upon breach of payment obligations by the Company 30 days        
Agreement termination description       The Definitive Agreement may be terminated by the Company on 30 days' notice and by Enumeral upon 60 days' notice of a material breach by the Company (or 30 days with respect to a breach of payment obligations by the Company), provided that the Company has not cured such breach and dispute resolution procedures specified in the Agreement have been followed.  
Research and development expense   $ 0   $ 1,000,000  
Maximum [Member] | License And Transfer Agreement [Member] | Enumeral Biomedical Holdings Inc [Member]          
Contingencies And Commitments [Line Items]          
Development milestones payment $ 37,800,000        
Sales milestones payment $ 67,500,000        
Percentage of reduction in royalty payment 50.00%